for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NanoCarrier Co., Ltd.

4571.T

Latest Trade

339.00JPY

Change

-2.00(-0.59%)

Volume

865,300

Today's Range

336.00

 - 

346.00

52 Week Range

226.00

 - 

585.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
341.00
Open
343.00
Volume
865,300
3M AVG Volume
29.85
Today's High
346.00
Today's Low
336.00
52 Week High
585.00
52 Week Low
226.00
Shares Out (MIL)
66.06
Market Cap (MIL)
22,393.46
Forward P/E
-9.29
Dividend (Yield %)
--

Next Event

Q3 2020 NanoCarrier Co Ltd Earnings Release

Latest Developments

More

NanoCarrier signs exclusive agreement for global study on new approach of using NC-6004 to treat head and neck cancer

NanoCarrier signs joint-development contract with Ceolia Pharma

NanoCarrier says basic agreement on international joint development of NC-6004 to treat head and neck cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NanoCarrier Co., Ltd.

NanoCarrier Co., Ltd. is a Japan-based biopharmaceutical products developer. The Company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It is engaged in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The Company’s product candidates include cisplatin micelle (NC - 6004), DACH-platin micelle (NC - 4016), epirubicin micelle (NC - 6300) and paclitaxel micelle (NK 105).

Industry

Biotechnology & Drugs

Contact Info

Chuou 144-15, 226-39, Wakashiba

+81.47.1977621

http://www.nanocarrier.co.jp

Executive Leadership

Tetsuhito Matsuyama

President, Chief Executive Officer, Representative Director

Takuma Nakatsuka

Chief Financial Officer, Director of Administration, Manager of President's Office, Board of Director

Hiroyuki Hanada

Chief Operating Officer, Director of Business Development, Director

Yasuki Kato

Chief Scientific Officer, Director

Ichiro Nakatomi

Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, JPY)
EPS (JPY)
Price To Earnings (TTM)
--
Price To Sales (TTM)
39.12
Price To Book (MRQ)
2.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-20.30
Return on Equity (TTM)
-19.70

Latest News

Latest News

BRIEF-NanoCarrier says business and capital alliance with Gene Techno Science and Noritsu Koki

* Says it plans business and capital alliance with Gene Techno Science Co Ltd and Noritsu Koki Co Ltd, regarding biopharmaceutical related business

BRIEF-VBL Therapeutics Receives Milestone Payment From Nanocarrier Under Licensing Agreement For VB-111 In Japan

* VBL THERAPEUTICS RECEIVES MILESTONE PAYMENT FROM NANOCARRIER UNDER LICENSING AGREEMENT FOR VB-111 IN JAPAN

BRIEF-NanoCarrier starts to discuss business alliance with Ceolia Pharma

* Says it starts to discuss business alliance with Ceolia Pharma Co., Ltd., and will cooperate on sale, manufacture and development of pharmaceuticals

BRIEF-NanoCarrier signs license preferential negotiating rights agreement with AccuRna

* Says it and AccuRna Inc entered into a preferential negotiating rights agreement on exclusive right to license of drug development based on co's gene delivery technology

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

BRIEF-Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan

* Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan

BRIEF-NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

* Says it and NanoCarrier Co., Ltd conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

BRIEF-NanoCarrier says orphan drug designation of NC-6004 by the U.S. FDA

* Says NC-6004, which is under development in the U.S. for biliary cancer, has been granted to the orphan drug designation from the U.S. FDA (Food and Drug Administration)

BRIEF-NanoCarrier receives orphan drug designation from FDA

* Says its micellar nanoparticles preparation NC-6300 for soft tissue sarcomas has been designated to orphan drug by Food and Drug Administration (FDA) in U.S.

BRIEF- NanoCarrier announces licenses contract with Todai TLO

* Says it signed a license contract with Todai TLO Ltd, regarding NC-6300 related high polymer micelle DDS

BRIEF- NanoCarrier to invest into Tocagen

NanoCarrier Co Ltd * Says it will invest into Tocagen Inc Source text in Japanese:https://goo.gl/zfV0hp Further company coverage: (Beijing Headline News)

BRIEF-NanoCarrier decides to resume phase III clinical trial of NC-6004

* Says it decides to resume phase III clinical trial of NC-6004

BRIEF-NanoCarrier signs joint research agreement with University of Utah

* Says it signed joint research agreement with Pharmaceutical Chemistry group (professor You H. Bae) of The University of Utah (U of U) on April 3

BRIEF-NanoCarrier forms cooperation with TPG Biologics Inc. on joint research

* Says the co formed cooperation with TPG Biologics Inc., a unit of Taiwan-based firm Center Laboratories Inc., on joint research

BRIEF-NanoCarrier gets substance patent grant in EU

* Says it received substance patent grant from European Patent Office

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up